After a Long Day of Travel, She Woke Up Unable to Walk. Then Crawled to Her Car and Drove to the ER (Exclusive)
Ella Katenkamp was days from finishing school when she woke up unable to walk
At first, she assumed the pain in her calves was from working out after a long trip
A week later, she left the hospital with a diagnosis that changed how she views her healthElla Katenkamp was days away from finishing school when she woke to a sharp, searing pain in her calves, her feet curled into a locked position and muscles frozen. What followed was a weeklong hospital stay, a terrifying diagnosis and a viral TikTok that sparked a conversation amongst millions.
'I took a trip the week before to Georgia, and it was a lot of, like, hiking,' Katenkamp tells PEOPLE, looking back on what seemed like a fun getaway before things spiraled. 'On the last day, we did a hike with thousands of stairs, and then I drove 13 hours straight back to Florida.'
The former college athlete wasted no time jumping back into her routine. 'As soon as I got back, I did a leg workout at the gym,' she says, noting that cramps didn't seem like a big deal at first.
'I got, like, really bad calf pain after that,' she explains. 'My feet locked into a pointed toe position, and I couldn't walk flat-footed. My calves were stuck like that.'
Assuming it was a standard athletic cramp, Katenkamp drank water, stretched, and went to bed. But by 5 a.m., the pain was excruciating, and her legs refused to move. 'I lived with a roommate at the time, but it was, like, five in the morning and I didn't want to wake her up,' she says. 'So I crawled to my car and drove myself to the hospital.'
https://people-app.onelink.me/HNIa/kz7l4cuf
At the ER, her condition worsened. 'As soon as I got in there, they ran over and put me in a wheelchair, and that was it for about a week,' she recalls. Throughout her hospital stay, walking was nearly impossible. 'If I walked at all, someone had to hold me up because I couldn't move my calves,' she says. 'They just stopped working.'
Doctors struggled to identify the cause of her symptoms. 'It took them about three or four days to figure it out,' Katenkamp notes. 'The nurses would come in and just be Googling my symptoms — no one knew what it was.'
Eventually, she received a diagnosis: rhabdomyolysis, a rare condition that causes muscle fibers to break down and release toxins into the blood. 'It's like the breakdown of your muscle to the point that it poisons your blood,' she explains.
Katenkamp was shocked to learn her creatine kinase (CK) level, a marker of muscle breakdown, was well above normal. 'Your CK level's not really supposed to be above 200, and when I got to the hospital, it was in the thousands,' she says.
Treatment involved flushing her system with fluids and monitoring her blood multiple times a day. 'They had to take my blood like three times a day,' she says. 'After two days, my CK level actually went up, which was really frustrating.'
By the time she was discharged, her CK level was still around 600–700. 'I wasn't where I was supposed to be, but I was starting to walk again,' she says. 'It was just my legs.'
Doctors attributed the onset to a combination of factors. 'They told me it was probably from the Red Bulls I drank in Georgia, not enough water, my birth control and going from sitting for 13 hours straight into an intense leg workout,' Katenkamp says.
The experience permanently changed her approach to fitness and health. 'I took a huge step back from energy drinks,' she shares. 'I didn't touch them for a long time, and now I only drink them very moderately.'
Once hyperactive with early-morning practices, classes and games, Katenkamp is now far more mindful. 'I drink so much more water now,' she says. 'And I definitely think about what days to go hard in the gym — like, was I sitting a lot the day before?'
The condition was new to her and to many. 'I had no idea what it was,' Katenkamp says. 'Even the doctors didn't know.'
She posted about the ordeal on TikTok, with the text overlay, 'She doesn't know it yet... but the next morning she was gonna crawl out of bed on all 4s and drive herself to the hospital at 6am to stay for the next week because her legs were paralyzed with rhabdomyolysis.'
While some followers offered support, others jumped to conclusions. But for Katenkamp, it was a moment that turned criticism into community. 'I didn't even really have to defend myself,' she says. 'Other people did it for me.'
Many shared their own experiences or those of loved ones. 'A lot of people said they'd been through something similar and knew how painful it was,' she says. 'There were tons of comments wishing me a good recovery.'
Looking back, she says the condition was more than just muscle cramps. 'My legs weren't even the same size when I left the hospital,' she says. 'It's definitely a process, but luckily, I'm past it now.'
Still, the risk of lasting damage was real. 'They say it can ruin your kidneys,' Katenkamp says. 'Luckily, I didn't get to that point, but if I hadn't gone to the hospital, it could have destroyed my organs.'
That's why her message is firm. 'It's more than just cramps,' she says. 'People kept saying, 'Push through it,' but I couldn't have done that — I had to go to the hospital.'
Two years later, Katenkamp's advice to others in recovery is simple and compassionate. 'Make sure you're taking care of yourself and read your body,' she says. 'Keep up with your water, stretch and don't overdo it.'
She encourages anyone experiencing similar symptoms to investigate all possibilities. 'Follow the steps your doctors give you,' Katenkamp adds. 'It can definitely come back.'
Never miss a story — sign up for to stay up-to-date on the best of what PEOPLE has to offer, from celebrity news to compelling human interest stories.
If she could tell social media users one thing, it's this: don't pretend to be an expert. 'You never know what's going on,' she says. 'There were over 20 different comments guessing the cause. It's different for every person.'
Katenkamp says she understands the appeal of quick judgments, especially online. But she hopes her story shows why empathy matters. 'Don't speak on other people's health,' she says. 'If there's one thing I learned, it's that you really don't know what someone's going through.'
Read the original article on People
Solve the daily Crossword

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Forbes
4 minutes ago
- Forbes
Monetizing Generative AI In Healthcare: Two Competing Paths
Generative AI is advancing faster than any technology in modern memory. When OpenAI released ChatGPT in late 2022, few in the medical community took notice. Most doctors saw it as a novelty, perhaps useful for administrative tasks or as a basic reference tool, but too unreliable for clinical care. In just a few years, that perception has shifted. Today's GenAI tools from companies like Google, Microsoft and Nvidia outperform most physicians on national medical exams and clinical challenges. Although none are currently recommended for patient use without physician oversight, that restriction is likely to be lifted soon. GenAI capabilities continue to double annually, and OpenAI's GPT-5 model is expected to launch within days. That raises a pressing question: How will generative AI be monetized in healthcare? Two competing visions are emerging. The first follows a familiar playbook: tech companies developing new FDA-approved tools for diagnosis and treatment. The second is clinician-led and would allow patients to use readily available, inexpensive large language models to manage their chronic diseases and assess new symptoms. To understand the advantages of each approach, it's first helpful to examine how different generative AI tools are from the AI applications used in medicine today. The Current Standard: Narrow AI Healthcare's traditional AI tools rely on technologies developed more than 25 years ago. Known as 'narrow AI,' these models are trained on large datasets to solve specific, well-defined problems. These applications are developed by training AI models to compare two datasets, detect dozens of subtle differences between them and assign a probability factor to each. For reliable results, the training data must be objective, accurate and replicable. That's why nearly all narrow AI tools are applied in visual specialties like radiology, pathology and ophthalmology — not cognitive fields that depend on subjective entries in the electronic medical record. Although these tools outperform clinicians, they are 'narrow' and can be used only for the specific task they were designed to complete. Take mammography, for example. Early-stage breast cancer can mimic benign conditions such as fibrocystic disease, causing radiologists to disagree when interpreting the same image. A narrow AI model trained on 10,000 mammograms (half from patients with confirmed cancer and half without) can detect far more differences than the human eye, resulting in 10-20% greater diagnostic accuracy than doctors. To evaluate narrow AI tools, the FDA assesses both the accuracy of the training data and the consistency of the tool's performance, similar to how it approves new drugs. This approach, however, doesn't work for generative AI. The development process and resulting technology are fundamentally different. The New Opportunity: Generative AI Today's large language models (LLMs) like ChatGPT, Claude and Gemini are trained on the near-totality of internet-accessible content, including thousands of medical textbooks and academic journals. This broad, in-depth training enables LLMs to respond to virtually any medical question. But unlike narrow AI, their answers are highly dependent on how users frame their questions, prompt the model and follow up for clarification. That user dependency makes traditional FDA validation, which relies on consistent and repeatable responses, effectively impossible. However, the multimodal nature of generative AI (working across writing, audio, images and video) opens a wide range of opportunities for clinicians. For example, I recently spoke with a surgeon who used ChatGPT to interpret a post-operative chest X-ray. The AI not only provided an accurate assessment, but it did so immediately, a full 12 hours before the radiologist issued a formal report. Had there been a serious problem that the surgeon failed to recognize, the LLM would have proven lifesaving. Even without formal approval, physicians and patients increasingly consult GenAI for medical expertise. While there's still debate over whether LLMs are ready for independent clinical use by patients, the pace of progress is breathtaking. Microsoft recently reported that its Diagnostic Orchestrator tool achieved 85.5% accuracy across 304 New England Journal of Medicine case studies, compared to only 20% for physicians. How Will Generative AI Be Monetized In Medicine? As generative AI becomes more powerful each year, two distinct approaches are emerging for how it might be monetized in healthcare. Each model has trade-offs: Medical care often fails to deliver optimal outcomes at a price patients can afford. This monetization model would seek to close those gaps. Take diabetes, where fewer than half of patients achieve adequate disease control. The result: hundreds of thousands of preventable and costly heart attacks, kidney failure and limb amputations each year. In other cases, patients struggle to access timely, affordable advice for new symptoms or for managing their multiple chronic conditions One way to solve these problems would be through GenAI tools built by entrepreneurial companies. Venture funding would allow startups to apply a process called distillation to extract domain-specific knowledge from open-source foundation models like DeepSeek or Meta's LLaMA. They would then refine these models, training them on radiologist interpretations of thousands of X-rays, transcripts from patient advice centers or anonymized recordings of conversations with patients. The result: specialized generative AI tools designed to address specific gaps in care delivery. Developing these tools will be expensive, both in terms of model training and the FDA approval process. Companies would also face legal liability for adverse outcomes. Still, if successful, these tools would likely command high prices and deliver substantial profits. Although less profitable than an FDA-approved device or bot, the second path to GenAI monetization would prove easier to develop, much less expensive and far more transformative. Rather than developing new software, this approach empowers patients to use existing large language models (ChatGPT, Gemini or Claude) to access similar expertise. In this model, clinicians, educators or national specialty societies — not private companies — would take the lead and share in the benefits. They would create low-cost instructional materials for various patient-learning preferences ranging from digital guides and printed pamphlets to YouTube videos and short training courses. These resources would teach patients how to use any of the publicly available large language models safely and effectively. Using these educational tools, patients would learn how to enter blood glucose readings from home monitors or blood pressure measurements from electronic cuffs. The large language model would then assess their clinical progress and suggest whether medication adjustments might be needed. Patients could also ask questions about new symptoms, receive likely diagnoses and learn when to seek immediate medical care. In conjunction with their physician, they could use GenAI's image and video capabilities to identify signs of wound infections and alert their surgeons. Those individuals with chronic heart failure could monitor their condition more closely and catch signs of decompensation early — allowing cardiologists to intervene before hospitalization becomes necessary. A GI specialist could identify complex intestinal conditions using daily patient-reported inputs, or a neurologist could diagnose ALS by analyzing videos of a patient's gait. Unlike startup models that require tens of millions in funding and FDA approval, these educational tools could be developed and deployed quickly by doctors and other clinicians. Because they teach patients how to use existing tools rather than offer direct medical advice, they would avoid many regulatory burdens and face reduced legal liability. And with 40% of physicians already working part-time or in gig roles, there are hundreds, or likely thousands, of experts ready to contribute. And since generative AI tools can provide information in dozens of languages and literacy levels, they would offer unprecedented accessibility. Which Path Will We Take? The two models aren't mutually exclusive, and both will likely shape the future of medicine. Given the potential for massive financial return from the first approach, we can assume that dozens of entrepreneurs are already developing disease-focused generative AI tools. But rather than waiting for technology companies to introduce GenAI tools, physicians working alone or in conjunction with educational companies have the opportunity to drive the process and improve our nation's health.

Associated Press
4 minutes ago
- Associated Press
Michael Heinley Joins Sam Brown Healthcare Communications As Managing Director, Client Development and Engagement
WAYNE, Pa. & NEW YORK--(BUSINESS WIRE)--Aug 4, 2025-- Sam Brown Healthcare Communications, a Blue Matter Company, is proud to announce the appointment of Michael Heinley to the new position of Managing Director, Client Development and Engagement, reporting to Founder and President Laura Liotta. This press release features multimedia. View the full release here: Michael Heinley With deep in-house and agency PR experience in the life sciences industry, Heinley is a highly seasoned counselor with a proven record of strategic communications impact across leading global organizations. These include senior leadership roles at Johnson & Johnson, Merck & Co., Inc., and WebMD. Most recently, as Senior Partner in the Finn Partners Global Health Practice, he led client development and engagement for pharmaceutical, biotech, health tech, med tech, health systems, professional societies, and advocacy organizations. 'In today's fast-moving and complex healthcare environment, Michael has a distinct perspective leading corporate, scientific, marketing, and brand storytelling campaigns that build trust, strengthen reputation, and deliver meaningful business results,' said Laura Liotta, Founder and President of Sam Brown. 'In this new role at Sam Brown, Michael will be instrumental in delivering innovative solutions, expanding our services and markets globally, and enabling our integrated teams to help clients adapt and lead in an evolving landscape.' Throughout his career, Heinley oversaw multiple global pharmaceutical product launches, R&D communications, employee engagement, financial/IR communications, reputation and issues management, CEO and C-suite counsel, and executive thought leadership. Heinley was named among the industry's most influential leaders and Mentor of the Year by PM360. He currently serves on the Board of Directors for Donate Life New York State, a statewide nonprofit dedicated to increasing organ and tissue donation. 'I'm thrilled to join the talented team at Sam Brown to help drive the agency's continued growth and success,' said Heinley. 'Under Laura's leadership, I've deeply admired the 'Sam Brownie' culture—recognized for building and sustaining enduring client partnerships through strategic expertise, hands-on senior counsel, and integrated creative excellence.' About Sam Brown Healthcare Communications For 26 years, Sam Brown has been a leading healthcare-focused corporate, clinical, and commercial communications agency for the life sciences industry. Sam Brown provides broad strategic communications services to a wide range of biotechnology, biopharmaceutical, and venture capital companies whose cutting-edge science and innovation impact human health. For more information, visit About Blue Matter Blue Matter is a strategic consulting firm serving the life sciences industry. From its offices in North America, Europe and Asia, Blue Matter serves pharmaceutical and biotech companies from around the globe. The firm helps clients maximize value at the product, portfolio, and organization levels. It has broad therapeutic expertise with a focus on complex markets such as oncology, CNS, and rare diseases. For more information, visit View source version on CONTACT: Media Contact: Christy Curran Sam Brown Inc. 615.414.8668 [email protected] KEYWORD: UNITED STATES NORTH AMERICA PENNSYLVANIA NEW YORK INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL PUBLIC RELATIONS/INVESTOR RELATIONS GENERAL HEALTH HEALTH CONSULTING COMMUNICATIONS PROFESSIONAL SERVICES SOURCE: Sam Brown Healthcare Communications Copyright Business Wire 2025. PUB: 08/04/2025 07:30 AM/DISC: 08/04/2025 07:30 AM

Associated Press
4 minutes ago
- Associated Press
Delta Development Team Solidifies Leadership and Continued Support in Prehospital Blood Space with Successful Series A3 Close
TUCSON, Ariz., Aug. 4, 2025 /PRNewswire/ -- In a U.S. market where fewer than 2% of EMS agencies have implemented prehospital blood programs—and over 70% of those rely on Delta Development Team (DDT) systems—DDT is emerging as the clear leader in a rapidly expanding space. Today, the company announced the successful close of its Series A3 funding round, marking a major milestone in its growth trajectory. Unlike many startups navigating a tight funding landscape, DDT completed its extended Series A round in just nine months. This momentum is a direct result of its increasing adoption across both civilian and military healthcare sectors, its growing reputation as the gold standard in cold chain technology, and its alignment with evolving protocols that prioritize earlier access to blood in the field. 'This market is transforming fast—and we're not just keeping pace; we're driving the shift,' said Montgomery Leija, CEO of Delta Development Team. 'From military partnerships to frontline EMS units, our systems are becoming foundational infrastructure for evolving prehospital blood programs.' The Series A3 round was backed by a mix of strategic capital and non-dilutive funding, including support from the U.S. Air Force's TACFI (SBIR) program. This funding structure enables DDT to scale quickly while minimizing dilution and operational risk. Investors Amongst other investors, this round attracted a consortium of top angel networks known for backing breakthrough healthcare and deep-tech ventures: About Delta Development Team (DDT) Delta Development Team is redefining emergency medical care through rugged, field-ready refrigeration, monitoring, and logistics systems. Its mission is to ensure frontline responders have the tools they need to deliver lifesaving blood and biologics when and where they're needed most. To learn more, visit or contact [email protected]. View original content to download multimedia: SOURCE Delta Development Team